Ivermectin - good for worms
In this video, scientist Dr Susan Oliver (with cameo appearances by her dog, Julie) go Back to the Science on ivermectin and look at why being an effective parasite treatment doesn't make it an effective anti-viral.
Links to studies:
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
https://doi.org/10.1016/j.antiviral.2020.104787
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
https://doi.org/10.1080/13102818.2020.1775118
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
https://doi.org/10.1038/s41586-020-2575-3
Moxidectin and ivermectin inhibit SARS-CoV-2 replication in Vero E6 cells but not in human primary airway epithelium cells
http://biorxiv.org/content/early/2021/06/21/2021.05.17.444467.abstract
Ivermectin for preventing and treating COVID‐19 - Cochrane Database of Systematic Reviews
https://doi.org//10.1002/14651858.CD015017.pub2
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial
https://doi.org/10.1186/s12879-021-06348-5
Links to studies:
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
https://doi.org/10.1016/j.antiviral.2020.104787
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
https://doi.org/10.1080/13102818.2020.1775118
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
https://doi.org/10.1038/s41586-020-2575-3
Moxidectin and ivermectin inhibit SARS-CoV-2 replication in Vero E6 cells but not in human primary airway epithelium cells
http://biorxiv.org/content/early/2021/06/21/2021.05.17.444467.abstract
Ivermectin for preventing and treating COVID‐19 - Cochrane Database of Systematic Reviews
https://doi.org//10.1002/14651858.CD015017.pub2
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial
https://doi.org/10.1186/s12879-021-06348-5